BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35179434)

  • 1. Circ_0067934 reduces JNK phosphorylation through a microRNA-545-3p/PPA1 axis to enhance tumorigenesis and cisplatin resistance in ovarian cancer.
    Yin Y; Li J; Rong J; Zhang B; Wang X; Han H
    Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):261-274. PubMed ID: 35179434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circ_0026123 promotes cisplatin resistance and progression of ovarian cancer by upregulating RAB1A through sequestering miR-543.
    Wei L; He W; Zhao H; Zhao P
    Anticancer Drugs; 2022 Nov; 33(10):1069-1080. PubMed ID: 36255068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circ_0007841 knockdown confers cisplatin sensitivity to ovarian cancer cells by down-regulation of NFIB expression in a miR-532-5p-dependent manner.
    Gao Y; Huang Y
    J Chemother; 2023 Apr; 35(2):117-130. PubMed ID: 35380509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis.
    Wang S; Li Z; Zhu G; Hong L; Hu C; Wang K; Cui K; Hao C
    J Ovarian Res; 2021 Nov; 14(1):154. PubMed ID: 34774079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circ TYMP1 Inhibits Carcinogenesis and Cisplatin Resistance in Ovarian Cancer by Reducing Smad2/3 Phosphorylation via a MicroRNA-182A-3p/TGF1B Axis.
    Rao Y; Zhang W; Li D; Li X; Ma Y; Qu P
    Contrast Media Mol Imaging; 2022; 2022():1032557. PubMed ID: 36072623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
    Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
    Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a.
    Lin C; Zheng M; Yang Y; Chen Y; Zhang X; Zhu L; Zhang H
    Bioengineered; 2022 Apr; 13(4):9829-9838. PubMed ID: 35412951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circular RNA circ_ASAP2 regulates drug sensitivity and functional behaviors of cisplatin-resistant gastric cancer cells by the miR-330-3p/NT5E axis.
    Sun Y; Ma J; Lin J; Sun D; Song P; Shi L; Li H; Wang R; Wang Z; Liu S
    Anticancer Drugs; 2021 Oct; 32(9):950-961. PubMed ID: 34016832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of circ-PIP5K1A overcomes resistance to cisplatin in ovarian cancer by miR-942-5p/NFIB axis.
    Sheng H; Wang X
    Anticancer Drugs; 2023 Feb; 34(2):214-226. PubMed ID: 36730637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circ_0020123 enhances the cisplatin resistance in non-small cell lung cancer cells partly by sponging miR-140-3p to regulate homeobox B5 (HOXB5).
    Wei D; Zeng J; Rong F; Xu Y; Wei R; Zou C
    Bioengineered; 2022 Mar; 13(3):5126-5140. PubMed ID: 35170372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTX Regulated miR-153-3p/FOXR2 to Promote Cisplatin Resistance in Ovarian Cancer.
    Liu M; Peng J
    Comput Math Methods Med; 2022; 2022():2318170. PubMed ID: 35651928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsa_circ_0007142 contributes to cisplatin resistance in esophageal squamous cell carcinoma via miR-494-3p/LASP1 axis.
    Chang N; Ge N; Zhao Y; Yang L; Qin W; Cui Y
    J Clin Lab Anal; 2022 May; 36(5):e24304. PubMed ID: 35312115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer.
    Liu X; Yin Z; Wu Y; Zhan Q; Huang H; Fan J
    Bioengineered; 2022 Feb; 13(2):3739-3750. PubMed ID: 35081867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of circ_0058357 as a regulator in non-small cell lung cancer cells resistant to cisplatin by miR-361-3p/ABCC1 axis.
    Chu D; Li P; Li Y; Shi J; Huang S; Jiao P
    Thorac Cancer; 2021 Nov; 12(21):2894-2906. PubMed ID: 34523261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin resistance and malignant behaviors of lung cancer cells are promoted by circ_0002360 via targeting miR-6751-3p to regulate the expression of ZNF300.
    Ding L; Li L; Tang Z
    Thorac Cancer; 2022 Apr; 13(7):986-996. PubMed ID: 35166026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circ_0025033 deficiency suppresses paclitaxel resistance and malignant development of paclitaxel-resistant ovarian cancer cells by modulating the miR-532-3p/FOXM1 network.
    Huang H; Yan L; Zhong J; Hong L; Zhang N; Luo X
    Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):275-286. PubMed ID: 35196944
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Yang H; Zhang X; Zhu L; Yang Y; Yin X
    DNA Cell Biol; 2021 Jun; 40(6):821-832. PubMed ID: 34030482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circ_0078607 increases platinum drug sensitivity via miR-196b-5p/GAS7 axis in ovarian cancer.
    Dai C; Dai SY; Gao Y; Yan T; Zhou QY; Liu SJ; Liu X; Deng DN; Wang DH; Qin QF; Zi D
    Epigenetics; 2023 Dec; 18(1):2175565. PubMed ID: 36908025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circ_0109291 Promotes Cisplatin Resistance of Oral Squamous Cell Carcinoma by Sponging miR-188-3p to Increase
    Gao F; Han J; Wang Y; Jia L; Luo W; Zeng Y
    Cancer Biother Radiopharm; 2022 May; 37(4):233-245. PubMed ID: 32758011
    [No Abstract]   [Full Text] [Related]  

  • 20. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer.
    Pang J; Ye L; Zhao D; Zhao D; Chen Q
    Cell Biol Int; 2020 Dec; 44(12):2416-2426. PubMed ID: 32808744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.